HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of “Hold” from Brokerages

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has been assigned a consensus rating of “Hold” from the seven brokerages that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $14.8667.

Several brokerages recently weighed in on HCM. Wall Street Zen raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Bank of America decreased their price target on HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Morgan Stanley set a $13.60 price objective on HUTCHMED in a report on Thursday, May 28th. The Goldman Sachs Group lowered their target price on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, July 23rd. Finally, Daiwa Securities Group raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Thursday, September 3rd.

Institutional Investors Weigh In On HUTCHMED

A number of hedge funds have recently added to or reduced their stakes in HCM. Janney Montgomery Scott LLC bought a new position in shares of HUTCHMED during the 1st quarter valued at $365,000. XY Capital Ltd lifted its holdings in HUTCHMED by 9.2% in the fourth quarter. XY Capital Ltd now owns 57,610 shares of the company’s stock valued at $768,000 after acquiring an additional 4,853 shares during the period. Finally, Amundi boosted its position in HUTCHMED by 4.0% in the first quarter. Amundi now owns 232,246 shares of the company’s stock worth $3,474,000 after purchasing an additional 8,916 shares during the last quarter. 8.82% of the stock is currently owned by hedge funds and other institutional investors.

HUTCHMED Price Performance

Shares of NASDAQ:HCM opened at $13.82 on Friday. The business has a fifty day moving average price of $12.21 and a 200-day moving average price of $12.63. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.50 and a current ratio of 5.64. HUTCHMED has a 1-year low of $9.77 and a 1-year high of $17.62.

HUTCHMED (NASDAQ:HCM) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.14 by ($0.09). The company had revenue of $139.14 million for the quarter, compared to the consensus estimate of $304.16 million. As a group, analysts anticipate that HUTCHMED will post 0.23 EPS for the current year.

About HUTCHMED

HUTCHMED (NASDAQ:HCM) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company combines drug research and development capabilities with commercial operations in China and international markets.

HUTCHMED’s oncology portfolio includes fruquintinib, marketed in China as Elunate and in the United States as Fruzaqla for certain patients with metastatic colorectal cancer. The company also develops other targeted therapies, including savolitinib, a MET tyrosine kinase inhibitor, and surufatinib, an angiogenesis and immunomodulatory therapy.